ATAI Life Sciences N.V. (ATAI) - Dilution Analysis

10-Q filing | 363.2M shares outstanding

8-K filing: Atai Beckley N.V. filed a prospectus supplement covering the resale of up to 5,316,238 common shares by certain selling securityholders to satisfy registration rights granted in connection with the acquisition of Beckley Psytech Limited.

8-K filing: The Company announced the closing of a public offering of 27,283,750 common shares at a price of $5.48 per share.

10-Q filing | 196.6M shares outstanding

8-K filing: atai Life Sciences N.V. entered into subscription agreements for a PIPE Financing involving the sale of 18,264,840 ordinary shares and a pre-funded warrant to purchase 4,566,210 common shares at $2.19 per share, resulting in gross proceeds of approximately $50 million. ($50.0M proceeds)

8-K filing: atai Life Sciences N.V. entered into a share purchase agreement to acquire Beckley Psytech Limited by issuing 105,044,902 ordinary shares and concurrently entered into subscription agreements for a PIPE Financing involving the sale of 9,993,341 common shares and a pre-funded warrant to purchase 6,311,006 common shares, resulting in gross proceeds of approximately $30 million. ($30.0M proceeds)

10-Q filing | 200.3M shares outstanding

10-K filing | 198.3M shares outstanding

8-K filing: atai Life Sciences N.V. entered into an underwriting agreement for a public offering of 26,190,477 common shares at $2.10 per share, with an option for the underwriter to purchase an additional 3,928,571 shares. ($55.0M proceeds)

10-Q filing | 160.6M shares outstanding

10-Q filing | 160.4M shares outstanding

10-Q filing | 158.9M shares outstanding

10-K filing | 158.8M shares outstanding

8-K filing: atai Life Sciences N.V. acquired 24,096,385 newly issued series C preferred shares of Beckley Psytech Limited for $39,999,999.10 and an additional 11,153,246 shares for $10,000,000.37. ($50.0M proceeds)

8-K filing: atai Life Sciences N.V. entered into a Termination and New Consultancy Agreement with ATAI Life Sciences AG and Christian Angermayer, granting Mr. Angermayer an option to purchase 1,658,094 shares of the Company that vests over four years.

8-K filing: atai Life Sciences N.V. acquired 24,096,385 newly issued series C preferred shares of Beckley Psytech Limited for $39,999,999.10 and will acquire 11,153,246 shares for $10,000,000.40 in a secondary sale. ($50.0M proceeds)

10-Q filing | 155.8M shares outstanding

10-Q filing | 155.8M shares outstanding

10-Q filing | 155.8M shares outstanding

10-K filing | 155.7M shares outstanding

10-Q filing | 156.6M shares outstanding

10-Q filing | 154.0M shares outstanding

S-3 filing: ATAI Life Sciences N.V. files an S-3 form to offer and sell up to $300,000,000 in the aggregate of common shares and debt securities from time to time in one or more offerings.

10-Q filing | 153.5M shares outstanding

10-K filing | 160.7M shares outstanding

10-Q filing | 160.3M shares outstanding

S-1/A filing: This S-1/A filing describes an offering of 14,286,000 common shares with an option for underwriters to purchase an additional 2,142,900 common shares, with an estimated $178 million in net proceeds based on an assumed IPO price of $14.00 per share.

S-1/A filing: This is an S-1/A filing. It discusses the issuance of common shares and includes information related to a lock-up agreement and potential conversion of shares in connection with a public offering or reorganization.

S-1/A filing: This is an S-1/A filing for an initial public offering of common shares by ATAI Life Sciences B.V., which will be converted into ATAI Life Sciences N.V. prior to closing. The company has granted underwriters an option to purchase additional shares. The net proceeds will be used as set forth in the 'Use of Proceeds' section.

S-1/A filing: This S-1/A filing details the terms of an agreement where the company will issue shares of common stock to the founder upon the achievement of certain milestones related to intellectual property development.

S-1 filing: The filing relates to the issuance of common shares in connection with various investments and agreements, including COMPASS investment, conversion of convertible promissory notes, and stock purchase agreements. It also discusses stock options, warrants, and rights related to the company's common stock.